Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kalaris Therapeutics (KLRS) Other Accumulated Expenses (2019 - 2020)

Kalaris Therapeutics (KLRS) has 2 years of Other Accumulated Expenses data on record, last reported at $97000.0 in Q3 2020.

  • For Q3 2020, Other Accumulated Expenses changed N/A year-over-year to $97000.0; the TTM value through Sep 2020 reached $97000.0, changed N/A, while the annual FY2019 figure was $147000.0, N/A changed from the prior year.
  • Other Accumulated Expenses reached $97000.0 in Q3 2020 per KLRS's latest filing, up from $42000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $147000.0 in Q4 2019 and bottomed at $42000.0 in Q2 2020.